Side-by-side · Research reference
ARA 290vsCerebrolysin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BPhase 3HUMAN-REVIEWED11/65 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
01Mechanism of Action
Parameter
ARA 290
Cerebrolysin
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Antibody development
Not reported in clinical trials
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
02Dosage Protocols
Parameter
ARA 290
Cerebrolysin
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Duration
28 days (Phase 2)Culver 2017
Corneal nerve improvements observed by day 28.
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Phase 3 RCT + observational
Timing
Any time of day
No circadian dependence reported.
—
Standard dose (stroke)
—
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
Lower dose (dementia)
—
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
Timing (stroke)
—
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
Adjunct to thrombectomy
—
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
Administration route
—
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Cerebrolysin
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
Cerebrolysin
Injection site reaction
Mild, transient
Mild pain, erythema (IM route)
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Infusion reaction
—
Rare: flushing, transient hypotension during rapid IV
Agitation / Restlessness
—
Reported in <5% of patients; typically mild, self-limited
Serious adverse events
—
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
Hemorrhagic transformation
—
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
Mortality
—
No increase; meta-analysis RR 0.89 (0.68-1.18)
Allergic reaction
—
Rare; porcine origin theoretically immunogenic but clinically insignificant
Seizure risk
—
Not elevated; safe in epilepsy populations
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
05Administration Protocol
Parameter
ARA 290
Cerebrolysin
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
6. Co-administration
—
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery